Table 2 Selected characteristics of cases and controls in this study. Sample size after quality control and genotyping platforms in each of the studies included in this study.
From: Identification of a novel uterine leiomyoma GWAS locus in a Japanese population
Stage | Sample Type | Source | Number | Age Mean ± Std | Genotyping Platform |
|---|---|---|---|---|---|
Stage 1: GWAS screening Stage 1 | |||||
case | BBJa | 5,720 | 44.8 ± 9.6 | OmniExpressExome BeadChip/OmniExpress and HumanExome | |
control | JPHCb, J-MICCc, IMMd, ToMMoe | 17,492 | 55.9 ± 10.0 | OmniExpressExome | |
Stage 2: Screening Stage 2 | |||||
case | BBJa | 8,026 | 64.9 ± 10.5 | OmniExpressExome BeadChip/OmniExpress and HumanExome | |
control | BBJa | 52,824 | 63.6 ± 15.7 | ||
Stage 3: Replication Stage | |||||
case | BBJa, KWBf | 3,483 | 63.8 ± 14.4 | Invader Assay | |
control | BBJa | 4,795 | 65.9 ± 14.1 | ||
